Travere Therapeutics, Inc. (TVTX)
63.47
+0.96
(+1.54%)
USD |
NASDAQ |
Sep 16, 16:00
63.48
+0.01
(+0.02%)
After-Hours: 16:35
Travere Therapeutics Enterprise Value : 6.015B for Sept. 15, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 15, 2026 | 6.015B |
| September 14, 2026 | 6.323B |
| September 11, 2026 | 6.359B |
| September 10, 2026 | 6.485B |
| September 09, 2026 | 6.364B |
| September 08, 2026 | 6.350B |
| September 04, 2026 | 6.275B |
| September 03, 2026 | 6.394B |
| September 02, 2026 | 6.459B |
| September 01, 2026 | 6.316B |
| August 31, 2026 | 6.370B |
| August 28, 2026 | 6.312B |
| August 27, 2026 | 6.486B |
| August 26, 2026 | 6.449B |
| August 25, 2026 | 6.438B |
| August 24, 2026 | 6.270B |
| August 21, 2026 | 6.316B |
| August 20, 2026 | 6.198B |
| August 19, 2026 | 6.339B |
| August 18, 2026 | 6.145B |
| August 17, 2026 | 6.111B |
| August 14, 2026 | 5.980B |
| August 13, 2026 | 5.913B |
| August 12, 2026 | 5.982B |
| August 11, 2026 | 5.798B |
| Date | Value |
|---|---|
| August 10, 2026 | 5.862B |
| August 07, 2026 | 5.903B |
| August 06, 2026 | 6.009B |
| August 05, 2026 | 6.038B |
| August 04, 2026 | 5.403B |
| August 03, 2026 | 5.305B |
| July 31, 2026 | 5.391B |
| July 30, 2026 | 5.522B |
| July 29, 2026 | 5.360B |
| July 28, 2026 | 5.393B |
| July 27, 2026 | 5.466B |
| July 24, 2026 | 5.530B |
| July 23, 2026 | 5.466B |
| July 22, 2026 | 5.426B |
| July 21, 2026 | 5.456B |
| July 20, 2026 | 5.352B |
| July 17, 2026 | 5.468B |
| July 16, 2026 | 5.334B |
| July 15, 2026 | 5.471B |
| July 14, 2026 | 5.501B |
| July 13, 2026 | 5.429B |
| July 10, 2026 | 5.457B |
| July 09, 2026 | 5.634B |
| July 08, 2026 | 5.624B |
| July 07, 2026 | 5.576B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| TG Therapeutics, Inc. | 8.321B |
| Krystal Biotech, Inc. | 9.128B |
| RenovoRx, Inc. | 68.52M |
| Pelthos Therapeutics, Inc. | 124.11M |
| ACADIA Pharmaceuticals, Inc. | 3.724B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -34.80M |
| Revenue (Quarterly) | 169.58M |
| Total Expenses (Quarterly) | 204.38M |
| EPS Diluted (Quarterly) | -0.3722 |
| Gross Profit Margin (Quarterly) | 96.22% |
| Profit Margin (Quarterly) | -20.52% |
| Earnings Yield | -1.20% |
| Normalized Earnings Yield | -0.7312 |